BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30978702)

  • 1. Estrogen receptor α regulates the expression of syndecan-1 in human breast carcinoma cells.
    Fleurot E; Goudin C; Hanoux V; Bonnamy PJ; Levallet J
    Endocr Relat Cancer; 2019 Jun; 26(6):615-628. PubMed ID: 30978702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.
    Nikolova V; Koo CY; Ibrahim SA; Wang Z; Spillmann D; Dreier R; Kelsch R; Fischgräbe J; Smollich M; Rossi LH; Sibrowski W; Wülfing P; Kiesel L; Yip GW; Götte M
    Carcinogenesis; 2009 Mar; 30(3):397-407. PubMed ID: 19126645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
    Qiao W; Liu H; Guo W; Li P; Deng M
    Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.
    Patki M; Salazar Md; Trumbly R; Ratnam M
    Biochem Biophys Res Commun; 2015 Feb; 457(3):404-11. PubMed ID: 25582774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes.
    Moggs JG; Murphy TC; Lim FL; Moore DJ; Stuckey R; Antrobus K; Kimber I; Orphanides G
    J Mol Endocrinol; 2005 Apr; 34(2):535-51. PubMed ID: 15821115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
    Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
    BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
    Thaler S; Schmidt M; Schad A; Sleeman JP
    Oncogene; 2012 Nov; 31(47):4912-22. PubMed ID: 22266866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen regulates miRNA expression: implication of estrogen receptor and miR-124/AKT2 in tumor growth and angiogenesis.
    Jiang CF; Li DM; Shi ZM; Wang L; Liu MM; Ge X; Liu X; Qian YC; Wen YY; Zhen LL; Lin J; Liu LZ; Jiang BH
    Oncotarget; 2016 Jun; 7(24):36940-36955. PubMed ID: 27175587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells.
    Williams C; Edvardsson K; Lewandowski SA; Ström A; Gustafsson JA
    Oncogene; 2008 Feb; 27(7):1019-32. PubMed ID: 17700529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
    Zhang X; Deng H; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases.
    Chute C; Yang X; Meyer K; Yang N; O'Neil K; Kasza I; Eliceiri K; Alexander C; Friedl A
    Breast Cancer Res; 2018 Jul; 20(1):66. PubMed ID: 29976229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.
    Al-Dhaheri MH; Rowan BG
    Mol Endocrinol; 2007 Feb; 21(2):439-56. PubMed ID: 17068199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronate synthase-2 overexpression alters estrogen dependence and induces histone deacetylase inhibitor-like effects on ER-driven genes in MCF7 breast tumor cells.
    Vanneste M; Hanoux V; Bouakka M; Bonnamy PJ
    Mol Cell Endocrinol; 2017 Mar; 444():48-58. PubMed ID: 28137613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 20. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
    Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
    Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.